Detection of Hepatocellular Carcinoma: Comparison of Gadoxetic Acid-Enhanced MRI, Diffusion-Weighted Imaging, and Combined Interpretation at 3 T MRI

Seung Hyun Park, MD¹, Yong Eun Chung, MD¹, Hye Suk Hong, MD², Ki Whang Kim, MD¹, Myeong-Jin Kim, MD³, Jin-Young Choi, MD¹

¹Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
²Department of Radiology, Hallym University College of Medicine, Seoul, Korea

Purpose: To compare diffusion-weighted imaging (DWI) and gadoxetic acid-enhanced (Gdx) magnetic resonance imaging (MRI), whether alone or in combination, for the detection of hepatocellular carcinoma (HCC) by using 3 T.

Materials and Methods: 84 HCCs in 66 patients (57 men, 9 women; mean age 69.2 years) were examined using 3 T MRI. DWI (b values 0, 50, and 800 sec/mm²) and dynamic gadoxetic acid-enhanced MRI as well as hepatobiliary phase were performed. Images were retrospectively reviewed by two radiologists to compare the diagnostic performances of DWI and Gdx MRI alone and in combination for the detection of HCC. Alternative free response receiver operating characteristic analysis and comparison of sensitivities were used for statistical analysis.

Results: The sensitivity of Gdx set (73/84, 87%) was significantly higher than that of DWI set (60.5/84, 72%) for both observers. The Az values of DWI and Gdx MRI for the detection of HCC were not statistically significant for either observer (Az for DWI = 0.818 and 0.864, Az for Gdx MR = 0.902 and 0.842, respectively, p = 0.107 for observer 1 and p = 0.738 for observer 2). The combination of both techniques did not increase the sensitivities of detecting HCC in either observer. When lesions smaller than 2 cm were considered, the DWI set yielded a significantly lower sensitivity as compared with either the Gdx set alone or the combination set.

Conclusion: Gadoxetic acid-enhanced MRI was better than DWI for detection of HCC by using 3 T MRI. The combination of DWI and Gdx MRI did not contribute to the successful detection of HCC.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the fifth most common tumor in the world, and the incidence of HCC has been increasing rapidly, especially in western countries (1, 2). Imaging diagnosis is essential for planning the treatment and management of HCC. Contrast-enhanced ultrasound, contrast-enhanced computed tomography (CT), and magnetic resonance imaging (MRI) have made it possible to accurately detect and characterize HCC (3-5). MRI is particularly useful due to its high tissue contrast and the availability of tissue-specific contrast agents. Various liver-specific MRI contrast agents have been introduced to increase the accuracy of hepatic imaging (6-8). Gadoxetic acid (Eovist or Primovist, Bayer Schering: Berlin, Germany) has been approved for hepatic imaging and is being widely used (9-12). It is a liver-specific hepatobiliary contrast agent which can also be used extracellularly. It is taken up by functioning hepatocytes and up to 50% is excreted into the bile (9, 13). There have
been several reports stating that gadoxetic acid-enhanced (Gdx) MRI improves the detection of HCC (4, 10, 11, 14). Furthermore, hepatobiliary phase imaging assists in surgical planning (14).

Recently, diffusion-weighted imaging (DWI) has been applied to liver MRI. DWI is sensitive to the molecular diffusion of water in biological tissues, and recent technological advancements in MRI have enabled the production of high quality DWI images on the liver. DWI is therefore often incorporated into routine liver MRI. It has been reported that DWI improves the accuracy of detection of hepatic metastases as compared to that of superparamagnetic iron-oxide (SPIO)-enhanced MRI (15). Moreover, higher signal to noise ratio at 3 T allows the use of higher b values, which are more sensitive to diffusion and less sensitive to transverse relaxation time (T2) and perfusion-related motion (16-18). However, the magnetic field inhomogeneities that degrade diffusion-weighted images are exacerbated at 3 T (19-21). It is important to assess the diagnostic value of DWI for the detection of HCC in a high field system because 3 T MRI is widely used for routine liver imaging (19, 20). To our knowledge, there has been no literature comparing the diagnostic performances of DWI and gadoxetic acid-enhanced MR imaging for the detection of HCC in the 3 T system. Therefore, the purpose of this study is to compare DWI, gadoxetic acid-enhanced MRI, and a combination of both techniques for the detection of HCC at 3 T.

**MATERIALS AND METHODS**

**Patients**

This study was approved by our institutional review board, and informed consent was not required due to its retrospective nature. By searching the radiological reports of the Department of Radiology between May 2007 and January 2009, a total of 143 patients who underwent gadoxetic acid-enhanced and diffusion-weighted MRI for evaluation of HCC were found. MRI examinations had been performed for ruled out or confirmed HCC because of suspected focal hepatic lesions on ultrasound or CT or due to elevated levels of serum tumor markers (alpha-fetoprotein or protein induced by vitamin K absence-II). The exclusion criteria were patients with a prior history of transarterial chemoembolization (TACE) (n = 60), radiofrequency ablation (n = 6), or more than five HCCs (n = 12). A total of 65 patients (56 men, 9 women; range 36-80 years, mean age 58.5 years) were included in this study. 49 patients had solitary lesions, 13 had two lesions, and three had three lesions. 51 patients had hepatitis B-related cirrhosis, 5 had hepatitis C-related cirrhosis, 2 had alcoholic cirrhosis, and the remaining 7 had no known underlying diseases. A total of 84 HCCs were identified in these 65 patients. A diagnosis of HCC was based on surgical findings (n = 31), percutaneous biopsy (n = 5), a typical clinical history and tumor marker levels in combination with lipiodol uptakes after TACE or the progressions of the disease as depicted on follow-up CT or MRI obtained at least one year after the initial imaging (n = 30).

**Magnetic Resonance Imaging**

All MRI examinations were performed using a 3 T imaging system (MAGNETOM Tim Trio, Siemens Healthcare sector, Erlangen, Germany), equipped with a phased-array coil (MAGNETOM Tim Trio, Siemens, Erlangen, Germany). We did not use any anti-peristaltic agents or oral contrast agents.

The MRI protocol consisted of a breath-hold transverse T1-weighted in- and out-of-phase two-dimensional gradient-recalled echo (GRE) sequence [repetition time (TR)/in-phase echo time (TE), 150/2.4 msec; out-of-phase TE = 1.2 msec; flip angle, 65°; field of view, 32-38 × 25-29 cm; matrix, 256 × 256; section thickness, 6 mm; slice spacing, 1.2 mm; one signal acquired; number of slices = 30]; a single slice turbo spin echo (TR/TE, 466/148; field of view, 32-36 × 25-29 cm; matrix, 288 × 230; section thickness, 4 mm; slice spacing, 1 mm) using the spectral fat suppression technique; and a breath-hold transverse three-dimensional (3D)-GRE (TR/TE, 2.5/0.9 msec; flip angle, 13°; field of view, 32-36 × 25-36 cm; matrix, 320 × 224; section thickness, 2 mm; no gap; acquisition time, 23 sec).

For contrast-enhanced dynamic MRI, the gadoxetic acid disodium (Eovist or Primovist, Bayer Schering; 0.025 mmol/kg) was injected as a rapid bolus, immediately followed by a saline flush of 15-20 mL. A 3D spoiled GRE sequence with chemically selective fat suppression was performed during suspended respiration 30-35 seconds (arterial phase), 65-70 seconds (portal phase), 100-120 seconds (hepatic venous phase) and five minutes (equilibrium phase) following the injection of the intravenous contrast agent. Additional hepatobiliary phase images were obtained 20 minutes after injection. An automatic infusion

**Comparison of EOB-MRI and DWI for Detection of HCC**

system (Sonic shot 50, Nemoto Kyorindo Co., Ltd., Tokyo, Japan) was used. The actual pulse sequence started manually when the fluoroscopic sequence revealed that the contrast material bolus had reached the abdominal aorta.

Respiratory-triggered fat-suppressed single-shot echo-planar diffusion-weighted imaging was performed in the transverse plane with tri-directional diffusion gradients by using three values (b values = 0, 50, 800 s/mm²). The other parameters for DWI were as follows: TR/TE, 2000/88; flip angle, 150 degrees; field of view, 400 mm; matrix, 192 × 108; section thickness, 5 mm; slice spacing, 6 mm; one signal acquired; number of slices = 96.

**Image Analysis**

Two radiologists (H.S.H., Y.E.C. with nine and five years of experience in abdominal imaging, respectively) independently reviewed three sets of MR images in random order: the DWI set [unenhanced T1-weighted images, DWI, and apparent diffusion coefficient (ADC) map]; the Gdx set (unenhanced, gadolinium-enhanced dynamic and hepatobiliary phase images); and a combination set of both techniques. The two observers were blinded to the patient history, laboratory results, findings of other imaging modalities and final diagnosis. The interval between the reviews of the two sets of images was at least one month. The criteria for diagnosis of HCC were as follows (12-14, 22, 23): I) a nodule with increased enhancement on arterial phase and washout on late venous or equilibrium phases; II) a nodule with arterial enhancement and hypointensity on hepatobiliary phase; III) a nodule larger than 1.5 cm with no uptake of contrast agent on hepatobiliary phase images; IV) a nodule showing hyperintensity on DWI and with almost equivalent or lower ADCs as compared with that of the surrounding liver parenchyma. Each observer recorded the possibility of HCC for each lesion with the following four-point confidence rating scale: 1, definitely not HCC; 2, probably not HCC; 3, indeterminate; 4, probably HCC; 5, definitely HCC. Lesions rated as a 4 or 5 were classified as positive. Each lesion was documented as accurately as possible according to sizes and segmental locations using the template. All images were reviewed using a local picture archiving and communication system monitor (Centricity; GE Medical systems, Milwaukee, WI, USA). By comparing the scoring results from the two observers with the standard of reference, we calculated the number of true-positive, true-negative, false-positive and false-negative lesions for each observer. Quantitative analyses of ADCs were not performed because the aim of this study was to compare the sensitivity for detections of HCC.

**Statistical Analysis**

Statistical analyses were performed using statistical software (SPSS version 14.0, SPSS Inc., Chicago, IL, USA; MedCalc version 9.3.6.0, Mariakerke, Belgium). An alternative-free response receiver operating characteristic (ROC) curve was fitted to each observer’s confidence ratings using maximum likelihood estimation. Sensitivity of MRI for detecting HCCs were calculated according to the lesion sizes. The generalized estimating equation method was used to compare the sensitivities, specificities, positive predictive values, and negative predictive values of the three MRI sets (Gdx, DWI, and the combined). Sensitivities were calculated as the number of true-positive lesions divided by the total number of HCCs. p values less than < 0.05 were considered statistically significant.

**RESULTS**

The areas under the ROC curve (Az) for each observer’s abili-

*Table 1. Area Under the Curve (Az) Values for the Detection of HCC*

<table>
<thead>
<tr>
<th>Size</th>
<th>Observer 1 Gdx Set</th>
<th>Observer 1 DWI Set</th>
<th>Observer 1 Combined Set</th>
<th>Observer 2 Gdx Set</th>
<th>Observer 2 DWI Set</th>
<th>Observer 2 Combined Set</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.908 (0.833-0.957)</td>
<td>0.820 (0.730-0.890)</td>
<td>0.860 (0.775-0.922)</td>
<td>0.851 (0.765-0.915)</td>
<td>0.863 (0.778-0.924)</td>
<td>0.878 (0.796-0.935)</td>
</tr>
<tr>
<td>≥ 2 cm</td>
<td>0.992 (0.932-0.996)*</td>
<td>0.918 (0.826-0.970)*</td>
<td>0.925 (0.836-0.974)</td>
<td>0.964 (0.889-0.993)</td>
<td>0.909 (0.815-0.965)</td>
<td>0.924 (0.834-0.974)</td>
</tr>
<tr>
<td>&lt; 2 cm</td>
<td>0.675 (0.477-0.836)</td>
<td>0.646 (0.447-0.813)</td>
<td>0.683 (0.485-0.842)</td>
<td>0.642 (0.443-0.810)</td>
<td>0.729 (0.533-0.876)</td>
<td>0.712 (0.515-0.864)</td>
</tr>
</tbody>
</table>

Note: *Numbers in brackets are the 95% confidence intervals.*

*The difference between Az values in the Gdx set and in the DWI set was significant (p = 0.04) for observer 1 when considering lesions larger than or equal to 2 cm.

Combined set = unenhanced, gadolinium-enhanced dynamic and hepatobiliary phase images, and diffusion-weighted images, DWI set = unenhanced, diffusion-weighted images, Gdx set = unenhanced, gadolinium-enhanced dynamic and hepatobiliary phase images, HCC = hepatocellular carcinoma.
Comparison of EOB-MRI and DWI for Detection of HCC

Fig. 1. Two hepatocellular carcinomas in a 48-year-old man.  
A. Gadoxetic-acid-enhanced MRI image during the arterial phase shows two enhancing masses, one in the right hepatic lobe (black arrow) and one in segment 4 (white arrow).  
B. A hepatobiliary phase image 20 minutes after contrast administration shows hypointense masses at the same locations (black and white arrows).  
C. Diffusion-weighted image (DWI) demonstrates a hyperintense lesion (arrow) at S4. However, the lesion in the right hepatic lobe is not depicted on DWI.  
D. Follow-up unenhanced CT one month after transarterial chemoembolization shows iodized oil retention in S4 and the right lobe.

Table 2. Comparison of Sensitivities among the Three Imaging Sets in the Detection of HCC

<table>
<thead>
<tr>
<th>Size</th>
<th>Observer 1</th>
<th>Observer 2</th>
<th>Combined Set</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gdx Set</td>
<td>DWI Set</td>
<td>Combined Set</td>
</tr>
<tr>
<td>All lesions (n = 84)</td>
<td>71/84 (85%)</td>
<td>57/84 (68%)*</td>
<td>77/84 (92%)</td>
</tr>
<tr>
<td>≥ 2 cm (n = 60)</td>
<td>56/60 (93%)</td>
<td>48/60 (80%)*</td>
<td>59/60 (98%)</td>
</tr>
<tr>
<td>&lt; 2 cm (n = 24)</td>
<td>15/24 (63%)</td>
<td>9/24 (38%)*</td>
<td>18/24 (75%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Size</th>
<th>Observer 1</th>
<th>Observer 2</th>
<th>Combined Set</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gdx Set</td>
<td>DWI Set</td>
<td>Combined Set</td>
</tr>
<tr>
<td>All lesions (n = 84)</td>
<td>75/84 (89%)</td>
<td>64/84 (76%)*</td>
<td>73/84 (87%)</td>
</tr>
<tr>
<td>≥ 2 cm (n = 60)</td>
<td>57/60 (95%)</td>
<td>54/60 (90%)</td>
<td>56/60 (93%)</td>
</tr>
<tr>
<td>&lt; 2 cm (n = 24)</td>
<td>18/24 (75%)</td>
<td>10/24 (42%)*</td>
<td>17/24 (71%)</td>
</tr>
</tbody>
</table>

Note. — Data are numbers of correct diagnoses; numbers in parentheses are percentages.  
*When lesions smaller than 2 cm were considered, the DWI set yielded a significantly lower sensitivity compared with those of either the Gdx set alone or the combination set (p = 0.0186, 0.0001 for observer 1, and p = 0.0005, 0.008 for observer 2, respectively). The sensitivity of observer 2 was not statistically significant for lesions larger than or equal to 2 cm (p = 0.1731).  
Combined set = unenhanced, gadolinium-enhanced dynamic and hepatobiliary phase images, and diffusion-weighted images; DWI set = unenhanced, diffusion-weighted images; Gdx set = unenhanced, gadolinium-enhanced dynamic and hepatobiliary phase images; HCC = hepatocellular carcinoma.

The diagnostic performance, including the sensitivities, specificities, with positive and negative predictive values for HCC detection for each reviewer and for each image set, is summarized.
in Table 3. For observer 2, specificity with DWI set was higher than Gdx set, while for observer 1, specificity with DWI set was lower than Gdx set. There were no significant differences among the mean positive predictive values and negative predictive values for the three image sets.

Eight lesions in 29 patients, which were confirmed via histopathological exam or imaging follow-up, but were not detected with a high confidence score of 4 or 5 by either observers on any image set, and were thus deemed false-negative lesions. In the Gdx lesion set, 14 lesions in 12 patients were not detected with high confidence by either of the observers. For the DWI set, 31 lesions in 27 patients were not detected with high confidence by either of the observers. All lesions detected in the DWI set were also seen in the Gdx set. Eight lesions (0.7-2.3 cm in size) were not noted in the DWI set, but were visualized in the Gdx set. The rates of false-positive reports for all lesions were 6.1% (6 of 98) for observer 1 and 7.1% (7 of 98) for observer 2, with a mean false positive rate of 2.5% (5 of 196) for Gdx set, 1.5% (3 of 196) for DWI set, and 4.5% (9 of 196) for combined set. In the Gdx set, four lesions in four patients were erroneously interpreted as positive findings, while in the DWI set, two lesions in two patients were erroneously interpreted as positive findings. The combined set showed five false-positive findings in five patients. On retrospective review, the false-positive interpretations for the Gdx set and combined set were attributed to presumed dysplastic nodules (Fig. 3).

DISCUSSION

This study found that gadoxetic acid-enhanced dynamic and hepatobiliary phase MRI is more sensitive for detecting HCC than the DWI when using 3 T MRI. Additions of DWI to gadoxetic acid-enhanced dynamic and hepatobiliary phase MRI did not increase the diagnostic performances for HCC detections. It has been indicated that detection and precise localization of HCC are known to be difficult with DWI alone because of its poor anatomic capabilities (24-26). Moreover, DWI has lower resolutions than hepatobiliary phase MRI and may lead to
important shortcomings of DWI are artifacts caused by cardiac motions and a susceptibility to artifacts caused by air (17, 26). Therefore, the subcardiac or subphrenic signal loss may significantly decrease the sensitivity for the detection of HCC in the left lobe or the hepatic dome. Our study results suggest that the degradation of DWI at 3 T outweighs the benefit of using DWI. Optimization of DWI at 3 T remains a work in progress, and future technical advancements could aid to overcome the low specificity and image quality of DWI.

Although DWI has been incorporated into the routine liver MRI protocol, it may not be helpful for diagnosis and characterization of HCC. DWI has been reported to be an unreliable predictor of local HCC recurrence after transarterial chemoembolization as compared to gadolinium-enhanced MRI (34), and it did not appear to contribute to the detection of HCC with well-differentiated components (31, 35). The limited performance of DWI for the detection of HCC is probably due to the cirrhotic or fibrotic background in patients with HCC. The presence of increased connective tissues in the cirrhotic liver is poor in protons and the decrease of blood flow results in restricted diffusions on DWI (18). Therefore, the lesion-to-liver contrast between the tumors and background liver may not be evident on DWI. Parikh et al. (25) found a sensitivity of 80.5% for HCC detection by DWI. In our study, the sensitivity (76%) was similar to the previous study for HCC detection using DWI, while increased sensitivity (89%) was achieved with dynamic and hepatobiliary phase imaging.

A hepatobiliary contrast agent provides both a dynamic and

**Fig. 3.** Hepatocellular carcinoma in a 45-year-old man.  
A. Gadoxetic acid-enhanced MR images during the arterial phase show two enhancing nodules in the left hepatic lobe (black and white arrows).  
B. The lesions show hypointensity on hepatobiliary phase images at the same location (black and white arrows).  
C. Only the lesion at S3 is visible on DWI using b values of 800 s/mm² (arrow).  
D. Follow-up CT shows compact iodized oil retention at S3. The lesion at S4 did not show any enhancement or washout during the follow-up period of one and a half years.  
Note. — DWI = diffusion-weighted imaging.
hepatobiliary phase. Previous studies have shown that a combination of dynamic imaging and a hepatobiliary phase improves HCC diagnostic performance (4, 14). Three-dimensional GRE MRI using a hepatobiliary contrast agent provides thin sections with no gaps, high signal-to-noise ratio, and high sensitivity for detecting sub-centimeter-sized hepatocellular lesions (5, 36-38). Three-dimensional GRE MRI also avoids the respiratory or susceptibility artifacts that are a problem in DWI. Therefore, gadoxetic acid-enhanced MRI appears to be better than DWI for the diagnosis of HCC when considering both diagnostic performances and image qualities of 3 T MRI.

Our results suggest that the addition of DWI to dynamic and hepatobiliary phase imaging may not be helpful for the detection of HCC. Nishie et al. (31) reported that an SPIO-enhanced MRI + DWI set outperformed the SPIO-enhanced set in HCC depiction when using a 1.5 T scanner. The average area under the ROC curve (Az) of the SPIO-enhanced MRI + DWI set (Az = 0.870) was significantly higher than that of SPIO-enhanced set (Az = 0.820) for detecting HCC. In our study, the combined interpretation of both DWI and gadoxetic acid-enhanced MRI did not increase the diagnostic performances of HCC detection. It has been reported that DWI may not contribute to the detections of HCC with well-differentiated components (27, 31). However, the gadoxetic acid-enhanced hepatobiliary phase of MR imaging has been reported to be useful for preoperative diagnosis of early HCC in a preliminary report (14). Therefore, gadoxetic acid-enhanced MRI appears to be more beneficial than DWI for depicting HCC. Cirrhotic patients with suspected HCC and impaired hepatobiliary enhancement due to decreased hepatic functions may benefit from DWI because it can detect HCCs in the absence of contrast materials (27). DWI can also be used for screening patients for hepatocellular lesions, by reducing the number of overlooked lesions.

HCC size is an important prognostic factor for patient survivals. Gadoxetic acid-enhanced dynamic and hepatobiliary phase of MRI have been reported to be helpful for the detection of small HCCs (4). However, DWI may simulate suspicious lesions and result in false-positive findings due to susceptibility artifacts. Sub-centimeter-sized hepatocellular lesions in the subphrenic space or left hepatic lobe may be missed due to artifacts. Furthermore, DWI with a high b value may not be superior to standard T2-weighted imaging in terms of lesion conspicuity of small HCCs in cirrhosis (39). In our study, when lesions smaller than 2 cm were considered, the DWI set had a significantly lower sensitivity as compared with either the Gdx set alone or the combination of both sets. However, small sized lesions (1-2 cm) only seen when using the hepatobiliary phase are also problematic. Because there are definite overlaps of size between early HCC and dysplastic nodules, indeterminate lesions may lead to false positive diagnoses. Further studies are needed to better define the criteria of early HCC.

Our study had several limitations. First, since we did not obtain a biopsy of every hepatic nodule, thus, not all lesions were histopathologically confirmed. However, if we had included only those lesions confirmed by histopathology, there would have been a chance of verification bias. Second, small (< 1.5 cm) nodules only seen on the hepatobiliary phase images were regarded as benign when there was no proven evidence of HCC during a follow-up period of one year. Given that an early HCC may require a substantial amount of time to increase in size, it may have been too early to determine whether those lesions were truly benign. The fates of indeterminate lesions should be documented in a long-term follow-up study. Third, optimization of DWI sequence parameters remains a work in progress for 3 T MRI. Further technical advancements could help overcome the problems of image quality in DWI while maintaining the specificity of 3 T MRI.

In conclusion, the gadoxetic acid-enhanced dynamic and hepatobiliary imaging was superior to DWI for detecting HCC with 3 T MRI. Additions of DWI to the dynamic and hepatobiliary imaging did not contribute to the detections of HCC.

REFERENCES

Comparison of EOB-MRI and DWI for Detection of HCC

AJR Am J Roentgenol 2009;192:1675-1681


with a standard T2-weighted sequence for detection of focal liver lesions. Invest Radiol 2008;43:261-266


간세포암의 발견: 3테슬라 자기공명영상에서 확산강조영상, Gadoxetic Acid 조영증강영상, 두 영상 조합의 비교

박승현¹ · 정용은¹ · 홍혜숙² · 김기황¹ · 김명진¹ · 최진영¹

목적: 간세포암의 발견에 있어 3 T 자기공명영상에서의 확산강조영상, gadoxetic acid 조영증강영상, 그리고 두 영상의 조합해석의 진단능을 비교하고자 한다.

대상과 방법: 3 T 자기공명영상에서 간세포암으로 의심된 66명의 환자(57명의 남자, 9명의 여자, 평균연령 69.2세)에서 84예의 간세포암을 대상으로 하였다. 확산강조영상(b값 0, 50, 800 sec/mm²)과 역동적 gadoxetic acid 조영증강영상을 얻었고 2명의 영상의학과 의사가 후향적으로 두 영상을 단독으로 혹은 조합하여 판독하였다. 통계분석은 receiver operating characteristic 곡선과 민감도의 비교를 통해 이루어졌다.

결과: Gadoxetic acid 조영증강영상군의 민감도(73/84, 87%)는 확산강조영상군의 민감도(60.5/84, 72%)보다 통계적으로 유의하게 높았다. 두 영상을 조합하여 판독해도 민감도가 높아지는 않았다. 확산강조영상군과 gadoxetic acid 조영증강영상군의 Az값은 통계적으로 유의한 차이를 보이지 않았다(관찰자 1, p = 0.107, 관찰자 2, p = 0.738). 병변이 2 cm 미만인 경우 확산강조영상군은 gadoxetic acid 조영증강영상군 혹은 두 영상의 조합군보다 더 낮은 민감도를 보였다.

결론: 간세포암의 발견에 있어 3 T 자기공명영상에서의 확산강조영상은 gadoxetic acid 조영증강영상보다 진단능이 낮다. 두 영상을 조합하여 판독해도 간세포암을 발견하는 데 있어서 진단능이 향상되는지는 않는다.

¹연세대학교 의과대학 세브란스병원 영상의학과, ²한림대학교 의과대학 영상의학과